Value Through Innovation15 August 2014

ToDAY®

cephapirin sodium

TODAY Proper Administration

View the video tutorial to learn how to properly administer TODAY in your dairy.

Why should you use TODAY in your dairy?

COMING SOON - Dairy producers share how using TODAY helps their herd.

New Studies

New studies from leading mastitis researchers have confirmed what we’ve known all along: Two treatments are as effective as five when treating mastitis.

Are you getting milked?

Check out this video that explains how a one-day treatment compares to extended therapy.

Mastitis. Setting the record straight.

From efficacy to the economic benefits and value of using fewer antibiotics, these pages will show you how and why TODAY tubes are what you need to manage mastitis on your dairy.

Product Description

TODAY treats gram-positive and gram-negative bacteria in lactating dairy cows. Using a convenient, single-day treatment, TODAY saves producers time and money when solving problems related to mastitis.

  • Single-day treatment against pathogens that cause mastitis
  • For use in lactating dairy cows
  • Takes advantage of the Opti-Sert® tip to aid in partial insertion

Presentations

  • Pail containing 144 x 10 mL syringes and 144 convenient single use alcohol pads.
  • Cartons containing 12 x 10 mL syringes with 12 convenient single use alcohol pads.
Features and Benefits

TODAY uses cephapirin sodium to treat susceptible gram-positive and gram-negative organisms, including penicillin-resistant Strep agalactiae and Staph aureus. It is for use in lactating dairy cows and treatment is accomplished in a single day, saving producers time and money when treating mastitis.
  • Unique Opti-Sert® tip helps prevent pushing harmful surface bacteria into the teat canal
  • Reduces the risk of new infections
  • Allows antibiotic contact with teat-canal infections
  • Provides the option of partial or full insertion with an exclusive, easy-to-use protective cap

Dosage Information

  • Infuse a 10 mL syringe (200 mg of cephapirin activity per syringe) once the quarter has been completely milked out
  • Repeat once only in 12 hours
  • For lactating cows only
  • Milk withdrawal: 96 hours after the last treatment
  • Slaughter withdrawal: 4 days after the last treatment
  • Overdosing may lead to a longer milk withdrawal
  • Read and follow label directions.

Safety Information:

PRECAUTIONS

ToDAY should be administered with caution to subjects which have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.

RESIDUE WARNINGS

  • Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food.
  • Treated animals must not be slaughtered for food until 4 days after the last treatment.
  • Administration of more than the prescribed dose may lead to residue of antibiotic in milk longer than 96 hours.

First-Generation Cephalosporin

In terms of judicious use of antibiotics, using a first-generation cephalosporin such as TODAY (cephapirin sodium) is recommended over the use of a third-generation cephalosporin (such as Spectramast® LC).1

Think Positive

Intramammary mastitis treatments of Gram-positive infections is widely reported as beneficial5, so those infections should be the focus of treatment.2

Efficacy

A recent study showed similar efficacy between TODAY and Spectramast LC.TODAY was not inferior to Spectramast LC for clinical or bacteriological cures.3

Economic Advantage

Two tubes of TODAY given according to the label will result in 60 fewer hours of milk withhold time as compared to using five tubes of Spectramast LC, and reduce time cows spend in the hospital pen by 35 percent. UsingTODAY can also save a 1,000 cow dairy over $13,000 annually.4

First Treatment of Choice

In a recent head-to-head study comparing cephapirin and ceftiofur (the active ingredient in Spectramast LC), the authors concluded, “Herds that do not utilize a culture-based approach for the treatment of clinical mastitis may have an economic benefit from selecting cephapirin with the shorter non-saleable milk duration as the first treatment of choice. This would be particularly true in herds that have an average or below-average incidence of Gram-negative organisms causing clinical mastitis.”3

1 Boddie RL, Nickerson SC and Sutherland SF. New design of mastitis tubes reduces infection. Hoard’s Dairyman 1989;134(13):579.

2 Keefe G, ManDonald K, Cameron M. On-Farm culture use experience and impact on antimicrobial use. University of Prince Edward Island, Charolottetown, PE, Canada.

3 Schukken YH, Zurakowski MJ, Rauch BJ, et al. Non-inferiority trial comparing a first-generation cephalosporin with athird-generation cephalosporin in the treatment of non-severe clinical mastitis in dairy cows.

4 Miltenburg JD, de Lange D, Crauwels AP, et al. Incidence of clinical mastitis in a random sample of dairy herds in the southernNetherlands. Vet Rec 1996;139(9):204–207.

5 Hess JL, Neuder LM, Sears PM. Rethinking clinical mastitis therapy. Presented at the 42nd Annual Meeting of the National Mastitis Council; Jan. 27, 2003; Fort Worth, TX.

 

 

Product Resources

    

 

Contact Information

  • Boehringer Ingelheim Vetmedica, Inc.

    Cattle Division

    3902 Gene Field Road
    St. Joseph, Missouri 64506

    • Phone 866-638-2226
    • Fax 816-326-9167


   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

    

Technical Bulletins

  • A Non-Inferiority Trial Comparing a First Generation Cephalosporin with a Third-Generation Cephalosporin in the Treatment of Non-Severe Clinical Mastitis in Dairy Cows.

  • Minimum Inhibitory Concentrations (MIC) for cephalosporin compounds on their active metabolites for selected mastitis pathogens.

  • Randomized Non-Inferiority Clinical Trial Evaluating Three Commercial Dry Cow Mastitis Preparations.